Enovix Corporation vs Zoetis Inc — how do they compare? Enovix Corporation trades at $4.78 (market cap $1.06B), while Zoetis Inc trades at $72.34 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 29.4× Enovix Corporation's market cap, and Zoetis Inc pays a 2.81% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | ZTS | |
|---|---|---|
Market Cap | $1.06B | $31.14B |
Sector | Technology | Health |
52-Week High | $13.19 | $156.76 |
52-Week Low | $3.68 | $71.91 |
Enterprise Value | $1.07B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.92, up 6.03% in the last 24 hours, with a bullish technical signal despite negative profitability. Recent earnings beats and the appointment of a former Apple executive as COO highlight operational progress. The stock shows strong analyst support with a consensus price target of $12.38, though cash flow remains negative as the company scales production.
Outlook is cautiously optimistic given high growth potential in advanced battery technology, but significant execution risks and persistent losses require careful monitoring. The stock offers upside if production ramps successfully, but volatility may persist near-term.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →